NovaBridge Biosciences Highlights Strong Clinical Data & Extends Cash Runway to Q4 2028

summarizeSummary

NovaBridge Biosciences released an updated investor presentation showcasing robust Phase 1b oncology data for Givastomig, promising interim Phase 2 ophthalmology data for VIS-101, and a solid financial position with cash runway extended to Q4 2028.

check_boxKey Events

• Robust Oncology Data

  Givastomig Phase 1b data shows 75% Objective Response Rate (ORR) and 16.9-month median Progression-Free Survival (mPFS) in 1L Gastroesophageal Adenocarcinoma (GEA), reinforcing its best-in-class potential. A randomized Phase 2 study is initiating in Q1 2026.

• Promising Ophthalmology Pipeline

  VIS-101 interim Phase 2 data indicates rapid and sustained vision improvement, with topline results expected in Q1 2026 and readiness to initiate Phase 3 by the end of 2026.

• Extended Financial Runway

  The company reports $228.3 million in cash, cash equivalents, and short-term investments as of September 30, 2025, providing operational runway until Q4 2028.

auto_awesomeAnalysis

This updated investor presentation provides a comprehensive overview of NovaBridge Biosciences' pipeline progress and financial health. The strong efficacy and durability data for Givastomig in Phase 1b, coupled with its best-in-class potential, significantly de-risks the lead oncology program. Positive interim Phase 2 results for VIS-101 further validate the company's ophthalmology platform. Crucially, the disclosed cash runway extending to Q4 2028 provides substantial operational stability, reducing near-term financing concerns and allowing the company to advance its clinical programs without immediate dilution pressure. Investors should monitor upcoming data readouts for VIS-101 in Q1 2026 and the initiation of Givastomig's randomized Phase 2 study.